BETA

IPO registrations (S-1, F-1) · Registrants

PRECISION BIOSCIENCES INC

SEC CIK
1357874 · filings on EDGAR ↗
Registration
Form S-1, first filed 2019-03-01, last 2019-03-18; 1 initial registration, 2 amendments
Outcome
Final prospectus filed 2019-03-28; declared effective 2019-03-27
Industry (SIC)
Biological Products, (No Diagnostic Substances) 2836
Incorporated in
DE
Business address
302 EAST PETTIGREW STREET, SUITE A-100, Durham, NC 27701
Ticker
DTIL (Nasdaq)
EDGAR entity type
operating
Insiders and CEO pay
PRECISION BIOSCIENCES INC on the corporate pages

Offering terms

Proposed price range
$15.00–$17.00 per share (S-1/A filed 2019-03-18)
Final price
$16.00 per share, within the range (424B4 filed 2019-03-28, an initial public offering)
Shares sold
7,900,000
Gross proceeds
$126,400,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol DTIL
Lead underwriters
J.P. Morgan; Goldman Sachs (2,607,000 shares); Jefferies (1,580,000 shares); Barclays (948,000 shares)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 6

FiledFormWhat it isName as filedEDGAR
2019-03-01S-1S-1 (registration)PRECISION BIOSCIENCES INC0001193125-19-061192 ↗
2019-03-13S-1/AS-1/A (amendment)PRECISION BIOSCIENCES INC0001193125-19-073065 ↗
2019-03-18S-1/AS-1/A (amendment)PRECISION BIOSCIENCES INC0001193125-19-077399 ↗
2019-03-27EFFECTEFFECT (declared effective)PRECISION BIOSCIENCES INC9999999995-19-000536 ↗
2019-03-28424B4424B4 (final prospectus)PRECISION BIOSCIENCES INC0001193125-19-090666 ↗
2020-06-11EFFECTEFFECT (declared effective)PRECISION BIOSCIENCES INC9999999995-20-001405 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2019-03-18S-1/Aregistration statement$15.00–$17.007,900,000-Nasdaq DTIL4primary document; range, shares headline, cover names 4document ↗
2019-03-28424B4final prospectus$16.007,900,000$126,400,000Nasdaq DTIL4primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
Adelman Robert JDirector,TenPercentOwner22019
ANSARI ABIDOfficerChief Financial Officer72019–2020
FMR LLCOther; TenPercentOwnerOther22019
GOODMAN COREY STenPercentOwner22019
JANTZ DEREKDirector,Officer; Director,Officer,TenPercentOwnerChief Scientific Officer192019–2022
KANE MATTHEW R.Director,Officer; Director,Officer,TenPercentOwnerPresident and CEO162019–2021
KHAZI FAYAZOfficerCEO of Elo Life Systems42019–2021
Schinazi Raymond FDirector72019–2022
Sharp ShaliniDirector32019–2021
SMITH J. JEFFERSONOfficer; TenPercentOwnerChief Research Officer182019–2026
THOMSON DAVID S.OfficerChief Development Officer; Chief Operating Officer102019–2021
venBio Global Strategic Fund, L.P.Director,TenPercentOwner22019
venBio Global Strategic GP, L.P.TenPercentOwner22019
venBio Global Strategic GP, Ltd.TenPercentOwner22019
YAO TONY DUNG LINGDirector42019
Scimeca DarioOfficerGeneral Counsel; General Counsel and Secretary262019–2026
Heery ChristopherOfficerChief Medical Officer32019–2020
Buehler KevinDirector162019–2026
Germano Geno JDirector142020–2026person page Fuzzy
Barton ShaneOfficerVP & Corporate Controller72021–2023
Kelly John AlexanderOfficerChief Financial Officer; Interim CFO332021–2026
Frankel StanleyDirector122021–2026
List AlanOfficerChief Medical Officer102021–2024
Amoroso MichaelDirector,OfficerPresident and CEO222021–2026
Pire Shari LisaDirector92021–2026
Wadsworth Samuel C.Director62021–2024
Brown MelindaDirector142022–2026
NOVARTIS AGTenPercentOwner12022
NOVARTIS PHARMA AGTenPercentOwner12022
Burris Mei Zhang LuOfficerChielf Accounting Officer12026
Gorsuch Cassandra LouiseOfficerChief Scientific Officer12026
Tanna Naresh HareshOfficerChief Financial Officer12026

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2019-03-15PRECISION BIOSCIENCES INCBiotechnology$70,000,000$39,550,000231
2018-06-08PRECISION BIOSCIENCES INCBiotechnology$110,000,000$88,075,013401
2015-05-12PRECISION BIOSCIENCES INCBiotechnology$25,650,000$25,650,000111

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationPRECISION BIOSCIENCES, INCNCState business registriesname and state
Plan sponsorPRECISION BIOSCIENCES, INC.NCForm 5500 (employee benefit plans)name and state
Federal award recipientPRECISION BIOSCIENCES, INC.NCFederal spending (USAspending)name and state
Form D issuerPRECISION BIOSCIENCES INCNCForm D private offeringsCIK (EXACT)
Patent assigneePrecision Biosciences, Inc.NCPatents (USPTO)name and state
SEC filerPRECISION BIOSCIENCES INCSEC filers (EDGAR)CIK (EXACT)
Trademark ownerPrecision BioSciences, Inc.NCTrademarks (USPTO)name and state
Person pageGeno J GermanoPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Biological Products, (No Diagnostic Substances), NC first:

More with this interest.

In other datasets, the same topic (Health) in NC:

Interests: Biological Products, (No Diagnostic Substances) · Health